tirzepatide shortage update Update: On December 19th the FDA ruled the tirzepatide was resolved, however is giving a grace period for compounding pharmacies to continuing manufacturing. This grace period is 60 days. On FDA Affirms Decision on Tirzepatide

The article says expired formulations may have exhausted their preservative systems, which allows microbial growth even when the product was stored correctly

Empagliflozin is not recommended for patients with severe renal impairment, end-stage renal disease, or those receiving dialysis because its effectiveness relies on the kidneys' ability to filter glucose from the blood

Visceral fat increases inflammation in the body and is strongly linked to high cholesterol and heart disease

Many lose weight multiple times but they cannot maintain that weight loss because their body has a different genetic make-up

The physician gives the patient her Depo injection at the end of the office visit

The inhibitor concentration necessary for 50% inhibition (IC 50 ) was determined with respect to a control (no inhibitor)